Consolidated revenue from operations rose 27.0% YoY to ₹755.9 Cr (₹595.3 Cr in Q1 FY26) and 15.0% QoQ from ₹657.1 Cr; PAT jumped 118.9% YoY to ₹90.4 Cr (₹41.3 Cr) and 30.3% QoQ (₹69.4 Cr), with basic EPS at ₹2.77 versus ₹1.27 a year ago and ₹2.13 last quarter. Neither the current nor the year-ago quarter carries an exceptional item, so the reported growth rate is also the clean underlying rate — profit growth comfortably outran revenue growth, the signal that makes this a margin-led beat rather than just a top-line story.
Operating margin (EBITDA/revenue-from-ops) expanded roughly 690 bps YoY to 14.58% (7.70% in Q1 FY26) and about 283 bps sequentially from 11.75%, while net margin widened to 11.62% of total income from 6.67% a year ago. The expansion tracks management's stated channel/brand-spend leverage playbook and clears the "double-digit operating margin" floor the company flagged ahead of results. Standalone (parent-only) PAT was ₹84.3 Cr on revenue of ₹696.3 Cr, up a slower 19.3% YoY — the gap versus consolidated's 27.0% points to subsidiaries and the JV (BBlunt salons, overseas units, BTM Ventures) growing faster than the parent book; readers comparing the two should note this divergence rather than treat either figure as the anomaly.
Against its own July 9, 2026 quarterly update, management had guided ~30% YoY underlying growth but explicitly flagged that reported-basis growth would land in the mid-20s because Flipkart changed its marketplace reporting convention, netting fulfilment/logistics costs before paying Honasa for goods sold. The actual 27.0% reported print sits inside that guided band, so this reads as a "met" on revenue, not a beat or a miss — margin came in ahead of the stated double-digit floor. No independent analyst PAT consensus for the quarter turned up in search, so the print cannot be graded against Street numbers; no separate management press-release commentary was available for this filing. On the legal front, the Dubai Cassation Court on July 29, 2026 upheld a ~₹4.3 Cr (AED1.75 mn) compensation order against Honasa in the RSM distributorship dispute, while a separately-seated Delhi arbitration tribunal (award dated May 14, amended June 26, 2026) went the other way, awarding Honasa ~₹25.5 Cr (AED9.92 mn) plus further damages from RSM — neither figure is booked in this quarter's P&L, since exceptional items are nil in both the current and comparative columns.
The board's June 23 approval to acquire a 58% stake in Fluence Pharma (remaining 42% over 5-7 years) and the incorporation of wholly-owned Honasa Health (nutraceuticals B2C, effective July 7, 2026) both sit outside this quarter's numbers but expand the portfolio the company is counting on to sustain its stated high-teens 5-year revenue CAGR and 500 bps EBITDA-margin-expansion target — a pace this quarter's 690 bps YoY OPM gain is already running ahead of. The next checkpoint is whether that margin trajectory holds as growth normalizes toward the ~30% underlying target (versus this quarter's mid-20s reported print) and whether the RSM arbitration award converts into an actual cash recovery.
